95 related articles for article (PubMed ID: 29557750)
1. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
2. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
3. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
[TBL] [Abstract][Full Text] [Related]
4. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract][Full Text] [Related]
5. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
6. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.
Liu Y; Cao M; Cai Y; Li X; Zhao C; Cui R
Front Cell Dev Biol; 2020; 8():95. PubMed ID: 32154250
[TBL] [Abstract][Full Text] [Related]
9. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
[TBL] [Abstract][Full Text] [Related]
10. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.
Gabler L; Jaunecker CN; Katz S; van Schoonhoven S; Englinger B; Pirker C; Mohr T; Vician P; Stojanovic M; Woitzuck V; Laemmerer A; Kirchhofer D; Mayr L; LaFranca M; Erhart F; Grissenberger S; Wenninger-Weinzierl A; Sturtzel C; Kiesel B; Lang A; Marian B; Grasl-Kraupp B; Distel M; Schüler J; Gojo J; Grusch M; Spiegl-Kreinecker S; Donoghue DJ; Lötsch D; Berger W
Acta Neuropathol Commun; 2022 Apr; 10(1):65. PubMed ID: 35484633
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression.
Lee YY; Ryu JY; Cho YJ; Choi JY; Choi JJ; Choi CH; Sa JK; Hwang JR; Lee JW
Cancer Cell Int; 2024 Jan; 24(1):43. PubMed ID: 38273381
[TBL] [Abstract][Full Text] [Related]
15. FGF19-Based Mini Probe Targeting FGFR4 for Diagnosis and Surgical Navigation of Hepatocellular Carcinoma.
Cai J; Lian C; Lu Z; Shang Q; Wang L; Han Z; Gu Y
J Med Chem; 2024 Mar; 67(5):3764-3777. PubMed ID: 38385325
[TBL] [Abstract][Full Text] [Related]
16. Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S
Schwarz M; Kurkunov M; Wittlinger F; Rudalska R; Wang G; Schwalm MP; Rasch A; Wagner B; Laufer SA; Knapp S; Dauch D; Gehringer M
J Med Chem; 2024 Apr; 67(8):6549-6569. PubMed ID: 38604131
[TBL] [Abstract][Full Text] [Related]
17. Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract][Full Text] [Related]
18. Engineering an
Harrison EN; Jay AN; Kent MR; Sukienik TP; LaVigne CA; Kendall GC
bioRxiv; 2024 May; ():. PubMed ID: 38766056
[TBL] [Abstract][Full Text] [Related]
19. Correction: FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
Oncogene; 2023 Oct; 42(43):3219. PubMed ID: 37704786
[No Abstract] [Full Text] [Related]
20. FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
Braun M; Piasecka D; Sadej R; Romanska HM
Br J Cancer; 2024 Apr; ():. PubMed ID: 38627607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]